Apyx Medical (APYX) Q4 Revenue Jumps 34.8% to $19.2M, Loss Narrows to $0.06/Share
Apyx Medical narrows Q4 loss to $0.06 per share as revenue surges 34.8% year-over-year to $19.2 million, with fiscal 2026…
ADVERTISEMENT
Earnings
Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings
**Cullinan Therapeutics Inc Reports Q4 2025 Results**
Prelude Therapeutics Inc (PRLD) Reports Wider Loss for FY25 vs. Estimates
**BREAKING: Prelude Therapeutics Reports Wider-Than-Expected Q4 Loss**
Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M
Prelude Therapeutics reports Q4 loss of $1.29/share, 616.7% wider than expected, despite revenue jumping to $12.1M from $6.5M sequentially.
Opus Genetics (IRD) Reports $0.80 Q4 Loss Despite 230% Revenue Surge to $14.2M
Opus Genetics posts $0.80 Q4 loss as revenue surges 230% year-over-year to $14.2M on collaboration activity.
SuRo Capital Corp (SSSS) Reports Wider Loss Q4 Estimates by 10.0%
**SuRo Capital Corp Reports Wider-Than-Expected Q4 Loss**
Priority Technology (PRTH) reports Q4 Adjusted EPS of $0.11, Revenue Up 8.8%
Priority Technology Holdings posted Q4 adjusted EPS of $0.27, up 621% year-over-year, with revenue climbing 8.8% to $247.1 million.
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate; Shares Surge 19%
Dyne Therapeutics narrows Q4 loss to $0.73/share vs $0.76 estimate; shares jump 19% as clinical-stage biotech shows sequential improvement.
Septerna (SEPN) Reports Narrower Q4 Loss of $0.24/Share as Revenue Climbs to $24.1M
Septerna reports Q4 loss of $0.24/share, wider than expected, as revenue climbs to $24.1M from minimal levels earlier in fiscal…
BETA Technologies Reports Wider Q4 Loss of $1.71/Share vs $0.47 Estimate, Guides 2026 Revenue to $130M-$135M
BETA Technologies reported a Q4 loss of $1.71/share vs expected $0.47 loss, but guided 2026 revenue to $130M-$135M as certification…